VOICED : Pfizer asegura que su vacuna anticovid para niños supera el 90% de eficacia

Pfizer announced that its COVID-19 vaccine is over 90% effective in preventing symptomatic cases in children aged 5 to 11. The FDA is set to review this data to decide on authorization. The study involved 2,250 participants and was conducted during the prevalence of the delta variant. No severe COVID-19 cases or rare side effects like myocarditis were observed, though the sample size was not large enough to detect very rare side effects. The vaccine dose for children is 10 micrograms, compared to 30 micrograms for older groups. The US government is prepared to start vaccinating children once authorized.

What percentage of effectiveness did Pfizer claim for their COVID-19 vaccine in children aged 5 to 11?

• 95%

• 70%

• 80%

• 90%

What was the primary variant of COVID-19 during the data collection for Pfizer's vaccine study?

• Alpha

• Beta

• Gamma

• Delta

What was the dosage of the Pfizer vaccine given to children in the study?

• 10 micrograms

• 30 micrograms

• 5 micrograms

• 20 micrograms

Which age group received a higher dosage of the Pfizer vaccine compared to children?

• Infants

• Teenagers

• Elderly

• Adults

What is the U.S. government's plan regarding the vaccination of children aged 5 to 11?

• Wait for more data

• Start immediately after authorization

• Delay until next year

• Conduct more trials